Skip to content
grad
Clinical Trials Portal

Clinical Trials Portal

Bon Secours Richmond Health System

  • Home
  • FAQs

Author: BSMHWebadmin

Alliance 212102

Alliance Protocol A212102, “Blinded Reference Set for Multicancer Early Detection Blood Tests”

 

https://www.clinicaltrials.gov/ct2/show/NCT05334069?term=NCT05334069&draw=2&rank=1

 

Read more about this trial →

← Back to available clinical trials

EA1151-TMIST

EA1151 Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Read more about this trial →

← Back to available clinical trials

S2001

“Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations”

Read more about this trial →

← Back to available clinical trials

A021703

RANDOMIZED DOUBLE-BLIND PHASE III TRIAL OF VITAMIN D3 SUPPLEMENTATION IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (SOLARIS)

Read more about this trial →

← Back to available clinical trials

URCC21038

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT):
A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

Read more about this trial →

← Back to available clinical trials

S1900E

A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)”

Read more about this trial →

← Back to available clinical trials

EA5182

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)(NCT04181060)

Read more about this trial →

← Back to available clinical trials

MK-3475-B49

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent

Read more about this trial →

← Back to available clinical trials

BO41843 (persevERA Breast Cancer)

A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Read more about this trial →

← Back to available clinical trials

NRG-GI008

COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)

Read more about this trial →

← Back to available clinical trials

Posts navigation

Page 1 Page 2 … Page 4 Next page

Want to Know More?

Our Department participates in the National Cancer Institute Community Oncology Research  Program (NCORP). We are currently the top accruing site for treatment trials within our NCORP. We would not be able to hold this achievement without each of our patients and our hard work is a testament to them!

Check out these informational videos provided by the National Cancer Institute to learn more about Clinical Research.

APPOINTMENTS AVAILABLE

To inquire about participation in a clinical trial, please contact us by phone at (804) 893-8717 or by email at rvaoncologyresearch@bshsi.org

See our FAQs

logo

logo logo

Bon Secours International | Sisters of Bon Secours USA | Bon Secours Health System
This page is managed by the Bon Secours Richmond Health System in Richmond, VA.
© 2017 Bon Secours Health System, Inc.

  • Yelp
  • Facebook
  • Twitter
  • Instagram
  • Email
Proudly powered by WordPress
Cleantalk Pixel